Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05734534
Other study ID # BFR
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2023
Est. completion date August 1, 2024

Study information

Verified date February 2023
Source University of Copenhagen
Contact Morten Hostrup
Phone +4535321595
Email mhostrup@nexs.ku.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to investigate the effect of different blood flow restriction (BFR) interventions on muscle function and adaptations both in healthy well-trained individuals and individuals diagnosed with COPD.


Recruitment information / eligibility

Status Recruiting
Enrollment 105
Est. completion date August 1, 2024
Est. primary completion date April 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria for participants with COPD group are: - Diagnosis with COPD Exclusion criteria participants in the COPD group are - Having experienced an acute exacerbation of COPD within the last 6 weeks (Study A) - Taking part in pulmonary rehabilitation within the last 3 months (Study A) - Presenting with a history of thromboembolic event in the lower limbs. Inclusion criteria for healthy participants are: - Age between 18 and 40 years. - Maximal oxygen uptake (VO2max) of >55 ml O2/kg/min for men and >50 ml O2/kg/min for women - BMI of <26 and normal ECG and blood pressure. Exclusion criteria for healthy participants are: - Smoking - chronic disease, - Use of prescription medication - Pain due to current or previous musculoskeletal injury - Resistance training more than once per week in the 12 months leading up to the intervention.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
BFR during training
Healthy participants and participants diagnosed with COPD will be randomized to either the BFR-ST and BFR-HIT or to HL-ST and HIT
BFR during rest
Participants experiencing acute exacerbation of their COPD requiring hospitalization will be randomized to either BFR-P, BFR-NMES or the control group throughout their hospitalization.

Locations

Country Name City State
Denmark August Krogh Building Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Morten Hostrup, PhD

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Muscle strength Maximal voluntary isometric contraction of m. quadriceps femoris Change assessed from before to after the intervention (6 weeks in study A, on average 7 days in study B)
Secondary Lean mass Lean mass assessed by dual X-ray absorptiometry (DXA) Change assessed from before to after the 6 week intervention
Secondary Maximal oxygen consumption VO2max during incremental exercise Change assessed from before to after the 6 week intervention
Secondary Skeletal muscle mitochondrial respiration High resolution respirometry Change assessed from before to after the intervention (6 weeks in study A, on average 7 days in study B)
Secondary Fiber cross-sectional area Immunohistochemistry to determine fiber cross-sectional area Change assessed from before to after the intervention (6 weeks in study A, on average 7 days in study B)
Secondary Myonuclei Immunohistochemistry to determine number of myonuclei Change assessed from before to after the intervention (6 weeks in study A, on average 7 days in study B)
Secondary Functional exercise capacity Number of repetitions achieved during a 1-minute sit-to-stand test Change assessed from before to after the 6 week intervention (only in individuals with COPD)
Secondary Satellite cells Immunohistochemistry to determine number of satellite cells Change assessed from before to after the intervention (6 weeks in study A, on average 7 days in study B)
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1